References

Insulin monotherapy versus insulin combined with other glucose-lowering agents in type 2 diabetes: a narrative review

10.5812/ijem.65600 · 2018 · External reference

Glucagon-like Peptide-1 receptor agonist use and pancreatic cancer risk in patients with chronic pancreatitis

10.3390/cancers18020179 · 2026 · External reference

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial

10.1016/s0140-6736(23)01127-3 · 2023 · External reference

Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes

10.1111/dom.14990 · 2023 · External reference

Patient adherence to medication requirements for therapy of type 2 diabetes

10.1111/j.1742-1241.2010.02544.x · 2011 · External reference

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation

10.1210/en.2009-1272 · 2010 · External reference

A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time

10.1038/s41598-020-73668-y · 2020 · External reference

The course of glaucoma during pregnancy: a retrospective case series

10.1001/archopht.124.8.1089 · 2006 · External reference

Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

10.1080/00325481.2021.1971461 · 2021 · External reference

GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials

10.1007/s12020-019-02055-z · 2019 · External reference

The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies

10.2147/cpaa.s82008 · 2016 · External reference

Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD)

10.2337/dci18-0033 · 2018 · External reference

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

10.1016/s0140-6736(21)00213-0 · 2021 · External reference

Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes

10.1056/nejmoa2502082 · 2025 · External reference

Latanoprost exposure in pregnancy

10.1016/j.ajo.2004.03.002 · 2004 · External reference

Biological actions and therapeutic potential of the glucagon-like peptides

10.1053/gast.2002.31068 · 2002 · External reference

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

10.1053/j.gastro.2011.02.018 · 2011 · External reference

Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials

10.1016/j.phrs.2024.107401 · 2024 · External reference

Management of patients with type 2 diabetes with once-weekly semaglutide versus dulaglutide, exenatide ER, liraglutide and lixisenatide: a cost-effectiveness analysis in the Danish setting

10.1007/s13300-019-0630-6 · 2019 · External reference

Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability

10.2337/dc11-s231 · 2011 · External reference

Intraocular pressure-lowering medications during pregnancy and risk of neonatal adverse outcomes: a propensity score analysis using a large database

10.1136/bjophthalmol-2020-316198 · 2021 · External reference

Antiglaucoma medications during pregnancy and the risk of low birth weight: a population-based study

10.1136/bjo.2008.157123 · 2009 · External reference

Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes

10.1056/nejmoa1901118 · 2019 · External reference

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial

10.1111/dom.14232 · 2021 · External reference

Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American heart Association

10.1161/cir.0000000000001040 · 2022 · External reference

Oral semaglutide in an East Asian population with overweight or obesity, with or without type 2 diabetes: the OASIS 2 randomized clinical trial

10.1001/jamainternmed.2025.3599 · 2025 · External reference

Pregnancy outcomes in the medical management of glaucoma: an international multicenter descriptive survey

10.1177/11206721231199774 · 2024 · External reference

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as metformin add-on in a Korean population with type 2 diabetes

10.1007/s13300-023-01515-0 · 2024 · External reference

Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial

10.1016/s2213-8587(25)00225-6 · 2025 · External reference

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

10.3389/fendo.2024.1431292 · 2024 · External reference

Risk of malignant Neoplasia with glucagon-like Peptide-1 receptor agonist treatment in patients with type 2 diabetes: a meta-analysis

10.1155/2019/1534365 · 2019 · External reference

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial

10.1093/eurheartj/ehae613 · 2025 · External reference

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

10.1056/nejmoa1607141 · 2016 · External reference

Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes

10.1056/nejmoa2501006 · 2025 · External reference

Topical intraocular pressure therapy effects on pregnancy

10.2147/opth.s36712 · 2012 · External reference

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

10.1016/s2213-8587(19)30192-5 · 2019 · External reference

Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly East Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial

10.1016/s2213-8587(23)00388-1 · 2024 · External reference

The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons

10.1002/hsr2.2165 · 2024 · External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

10.1371/journal.pmed.1003583 · 2021 · External reference

Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes

10.1056/nejmoa2403347 · 2024 · External reference

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

10.1016/s2213-8587(18)30024-x · 2018 · External reference

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

10.1016/s0140-6736(19)31271-1 · 2019 · External reference

Anti-glaucoma medication exposure in pregnancy: an observational study and literature review

10.1111/j.1444-0938.2010.00526.x · 2010 · External reference

Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial

10.1210/jc.2018-00070 · 2018 · External reference

Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial

10.1001/jama.2021.3224 · 2021 · External reference

Weight-lowering effects of glucagon-like Peptide-1 receptor agonists and detection of breast cancer among Obese women with diabetes

10.1097/ede.0000000000001196 · 2020 · External reference

Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study

10.1007/s00125-023-05972-x · 2023 · External reference

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

10.1016/s2213-8587(17)30013-x · 2017 · External reference

RoB 2: a revised tool for assessing risk of bias in randomised trials

10.1136/bmj.l4898 · 2019 · External reference

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group

10.1001/jama.283.15.2008 · 2000 · External reference

IDF diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045

10.1016/j.diabres.2021.109119 · 2022 · External reference

Incretin based therapy and pancreatic cancer: realising the reality

10.3748/wjg.v28.i25.2881 · 2022 · External reference

Future perspectives in diabesity treatment: semaglutide, a glucagon-like peptide 1 receptor agonist (review)

10.3892/etm.2021.10601 · 2021 · External reference

Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1-5 trials

10.1111/dom.13331 · 2018 · External reference

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

10.1016/s2213-8587(20)30075-9 · 2020 · External reference

GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS

10.3389/fphar.2022.925377 · 2022 · External reference

Effects of dapagliflozin on cardiovascular outcomes in type 2 diabetes: study protocol of a randomized controlled trial

10.1097/md.0000000000022660 · 2020 · External reference

Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PioNEER 8 trial

10.2337/dc19-0898 · External reference

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

10.1016/s2213-8587(19)30066-x · External reference